A Randomized Phase 2A, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Safety and Effectiveness of Collagenase Clostridium Histolyticum in the Treatment of Dupuytren Disease Nodules

Author(s):

Bronier Costas ◽

Stephen Coleman ◽

Gregory Kaufman ◽

Robert James ◽

Brian Cohen ◽

...

Keyword(s):

Collagenase Clostridium Histolyticum ◽

Double Blind ◽

Double Blind Placebo ◽

Clostridium Histolyticum ◽

Dose Ranging ◽

Dupuytren Disease

Phase 2a, randomized, double-blind, placebo-controlled dose-ranging study of repeat doses of collagenase clostridium histolyticum for the treatment of edematous fibrosclerotic panniculopathy (cellulite)

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2015.02.086 ◽

2015 ◽

Vol 72 (5) ◽

pp. AB19 ◽

Keyword(s):

Collagenase Clostridium Histolyticum ◽

Double Blind ◽

Double Blind Placebo ◽

Clostridium Histolyticum ◽

Faculty Opinions recommendation of A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717967956.793467610 ◽

2012 ◽

Author(s):

Robin Steinhorn

Keyword(s):

Pulmonary Arterial Hypertension ◽

Arterial Hypertension ◽

Sildenafil Citrate ◽

Double Blind ◽

Double Blind Placebo ◽

Treatment Naïve ◽

Dose Ranging ◽

Pulmonary Arterial

A phase II, randomized, double‐blind, placebo‐controlled, dose‐ranging study to evaluate the efficacy and safety of VT‐1161 oral tablets in the treatment of patients with distal and lateral subungual onychomycosis of the toenail

British Journal of Dermatology ◽

10.1111/bjd.19224 ◽

2020 ◽

Author(s):

B. Elewski ◽

S. Brand ◽

T. Degenhardt ◽

S. Curelop ◽

R. Pollak ◽

...

Keyword(s):

Phase Ii ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Relapsing Remitting Multiple Sclerosis

Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study

The Lancet Neurology ◽

10.1016/s1474-4422(08)70173-x ◽

2008 ◽

Vol 7 (9) ◽

pp. 796-804 ◽

Cited By ~ 326

Author(s):

Benjamin M Segal ◽

Cris S Constantinescu ◽

Aparna Raychaudhuri ◽

Lilianne Kim ◽

Rosanne Fidelus-Gort ◽

...

Keyword(s):

Multiple Sclerosis ◽

Phase Ii ◽

Double Blind ◽

Subcutaneous Injections ◽

Double Blind Placebo ◽

Relapsing Remitting ◽

Dose Ranging ◽

Remitting Multiple Sclerosis ◽

Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial

The Lancet ◽

10.1016/s0140-6736(16)30307-5 ◽

2016 ◽

Vol 388 (10039) ◽

pp. 31-44 ◽

Cited By ~ 446

Author(s):

Sally Wenzel ◽

Mario Castro ◽

Jonathan Corren ◽

Jorge Maspero ◽

Lin Wang ◽

...

Keyword(s):

Inhaled Corticosteroids ◽

Persistent Asthma ◽

High Dose ◽

Efficacy And Safety ◽

Pivotal Phase ◽

Double Blind ◽

Double Blind Placebo ◽

Dose Ranging ◽

Long Acting ◽

Β2 Agonist

134 Peyronie's disease symptom bother reduction is related to penile curvature improvement in response to treatment with collagenase clostridium histolyticum: Results from two large double-blind, randomized, placebo-controlled phase 3 studies

European Urology Supplements ◽

10.1016/s1569-9056(15)60136-1 ◽

2015 ◽

Vol 14 (2) ◽

pp. e134 ◽

Author(s):

L.I. Lipshultz ◽

H. Sadeghi-Nejad ◽

J. Mills ◽

J.P. Tursi ◽

T.M. Smith ◽

...

Keyword(s):

Peyronie’S Disease ◽

Disease Symptom ◽

Response To Treatment ◽

Penile Curvature ◽

Collagenase Clostridium Histolyticum ◽

Phase 3 ◽

Double Blind ◽

Clostridium Histolyticum ◽

Symptom Bother ◽

Peyronie's Disease

A randomized, double-blind, placebo-controlled, dose-ranging study of lisdexamfetamine dimesylate augmentation for major depressive disorder in adults with inadequate response to antidepressant therapy

Journal of Psychopharmacology ◽

10.1177/0269881117722998 ◽

2017 ◽

Vol 31 (9) ◽

pp. 1190-1203 ◽

Cited By ~ 5

Author(s):

Cynthia Richards ◽

Dan V Iosifescu ◽

Rajnish Mago ◽

Elias Sarkis ◽

James Reynolds ◽

...

Keyword(s):

Major Depressive Disorder ◽

Depressive Disorder ◽

Antidepressant Therapy ◽

Inadequate Response ◽

Major Depressive ◽

Lisdexamfetamine Dimesylate ◽

Double Blind ◽

Double Blind Placebo ◽

The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial

The Lancet ◽

10.1016/s0140-6736(11)61126-4 ◽

2011 ◽

Vol 378 (9792) ◽

pp. 676-683 ◽

Cited By ~ 216

Author(s):

John GF Cleland ◽

John R Teerlink ◽

Roxy Senior ◽

Evgeny M Nifontov ◽

John JV Mc Murray ◽

...

Keyword(s):

Heart Failure ◽

Cardiac Function ◽

Systolic Heart Failure ◽

Phase 2 ◽

Cardiac Myosin ◽

Double Blind ◽

Double Blind Placebo ◽

Phase 2 Trial ◽

Omecamtiv Mecarbil ◽

Antiviral activity of low-dose alovudine in antiretroviral-experienced patients: results from a 4-week randomized, double-blind, placebo-controlled dose-ranging trial

HIV Medicine ◽

10.1111/j.1468-1293.2007.00444.x ◽

2007 ◽

Vol 8 (3) ◽

pp. 142-147 ◽

Cited By ~ 10

Author(s):

J Ghosn ◽

A-M Quinson ◽

ND Sabo ◽

L Cotte ◽

C Piketty ◽

...

Keyword(s):

Antiviral Activity ◽

Low Dose ◽

Double Blind ◽

Double Blind Placebo ◽

Plecanatide, a Novel Uroguanylin Analog: A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate Efficacy and Safety in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

The American Journal of Gastroenterology ◽

10.14309/00000434-201410002-01831 ◽

2014 ◽

Vol 109 ◽

pp. S541 ◽

Cited By ~ 16

Author(s):

Philip Miner ◽

Robert DeLuca ◽

Marianela La Portilla ◽

Eveline Padila ◽

William Koltun ◽

...

Keyword(s):

Irritable Bowel Syndrome ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Dose Ranging ◽

Irritable Bowel